Dermalive, which is produced by Dermatech and Montreal-based Vivier Pharma and distributed by Intradermal Distribution, is in the middle of a controversy. Dermalive is an injectable filler technology, which constitutes of acrylic hydrogel particles suspended in a hyaluronic acid solution. There have been many dissatisfied customer who have used the product and have filed a case against Health Canada and the above mentioned companies after her face was disfigured following its use.

Case Highlights
a. Many patients have reported severe facial deformities after the treatment.
d. Dermalive was approved by Health Canada in 2003 but is now suspended after 8 cases of complaints were logged this year.
e. It's use as a medical device is suspended in France and the United States.
f. In Europe, this product is being scrutinized following legal suits in Europe.

Product Highlights
a. It contains acrylic hydrogel particles suspended in a hyaluronic acid solution.
b. It stimulates collagen growth in the soft tissue.
c. This plumps out dimples and wrinkles.
d. Results are visible within a few months.
e. Its use can lead to painful lumps at injection sites.
f. It can also cause the lips to swell up, become distorted and blistered.